Sastasundar Ventures Limited has informed the Exchange about Agreements
HEALTHX · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 2.0 pts less than Nifty Microcap 250 and 2.5 pts less than its Healthcare Service Provider peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Health X Platform Limited (formerly Sastasundar Ventures) has executed a Tripartite Agreement with its material subsidiary Sastasundar Healthbuddy Limited (SHBL) and Envision India Fund, a Mauritius-based qualified institutional buyer. This follows a Share Purchase Agreement dated 25.02.2026 under which Envision will acquire Mitsubishi Corporation's entire stake in SHBL. Post-transaction, SHBL's shareholding will be: HealthX holding 17,100,160 equity shares, Rohto Pharmaceuticals holding 3,562,064 shares, and Envision holding 1,013,766 shares, totalling 21,675,990 shares. The agreement contemplates a scheme of arrangement to merge SHBL into HealthX while preserving Envision's economic interest. If the merger is not completed, a share swap will be undertaken so Envision receives equivalent HealthX shares. Envision also gets the right to nominate one director to HealthX's board upon material breach or non-completion of the merger.
This is a meaningful structural change for shareholders — a new foreign institutional investor is entering the group, and the proposed merger of the material subsidiary could result in fresh share issuance and dilution for existing HealthX shareholders. The eventual swap ratio in the merger scheme will be the key number to watch. Director nomination rights for Envision also mean a potential change in board composition.